Tirbanibulin KX2-391 is a small molecule inhibitor of the Src kinase pathway. It is currently being studied as a potential treatment for various types of cancers, including basal cell carcinoma and cutaneous squamous cell carcinoma. Tirbanibulin KX2-391 was first developed by Kinex Pharmaceuticals and has undergone several clinical trials.
Chemical Name
The chemical name of Tirbanibulin KX2-391 is (E)-N-(7-chloro-4-(1-methyl-1H-pyrazol-5-yl)quinolin-3-yl)-4-(dimethylamino)but-2-enamide.
Molecular Formula
The molecular formula of Tirbanibulin KX2-391 is C20H22ClN5O.
Formula Weight
The formula weight of Tirbanibulin KX2-391 is 383.88 g/mol.
CAS No.
The CAS number of Tirbanibulin KX2-391 is 897016-82-9.
Top Ten Keywords from Google and Synonyms
Synonyms: KX2-391, KX-01, KX-01L, N-{7-chloro-4-[(1-methyl-1H-pyrazol-5-yl)quinolin-3-yl]-1,3-dihydro-2H-indol-2-ylidene}-N-methylmethanamine monohydrochloride
Health Benefits of Tirbanibulin KX2-391
Tirbanibulin KX2-391 has shown promising results in treating various types of skin cancers, particularly basal cell carcinoma and cutaneous squamous cell carcinoma. By inhibiting the Src kinase pathway, Tirbanibulin KX2-391 works to slow or stop the growth and spread of cancer cells.
Potential Effects
Clinical studies have shown that Tirbanibulin KX2-391 can effectively treat basal cell carcinoma and cutaneous squamous cell carcinoma. In one phase II study, researchers found that Tirbanibulin KX2-391 was well-tolerated and showed signs of efficacy in patients with these types of skin cancers.
Product Mechanism
Tirbanibulin KX2-391 works by specifically targeting the Src kinase pathway, a signaling pathway that is often activated in cancer cells and plays a key role in regulating cell growth and survival. By inhibiting this pathway, Tirbanibulin KX2-391 suppresses the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
Safety
Tirbanibulin KX2-391 has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, vomiting, and diarrhea. More severe side effects may occur in some patients, such as liver damage or allergic reactions. Patients should be closely monitored for any adverse reactions while taking Tirbanibulin KX2-391.
Side Effects
The most common side effects of Tirbanibulin KX2-391 include:
More severe side effects may occur in some patients, such as:
Dosing Information
The dosing of Tirbanibulin KX2-391 depends on the type of cancer being treated and other individual factors. It is typically administered topically in gel form, either alone or in combination with other cancer therapies. The recommended dose varies depending on the clinical trial or physician's discretion.
Conclusion
In conclusion, Tirbanibulin KX2-391 is a promising drug candidate for cancer therapy, particularly in the treatment of various types of skin cancers. As an inhibitor of the Src kinase pathway, it shows potential in slowing or stopping cancer progression in tumors that overexpress this pathway. While further clinical trials are needed to determine its efficacy and safety, Tirbanibulin KX2-391 represents an important step towards precision medicine and molecular targeted therapy in cancer treatment
